The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism

Whitney S. Thompson(Mayo Clinic), Joseph B. Lillegard(Mayo Clinic), Robert A. Kaiser(Mayo Clinic in Florida), Gourish Mondal(Mayo Clinic in Florida), Caitlin J. VanLith(Mayo Clinic in Florida)
Expert Opinion on Orphan Drugs
July 2, 2020
Cited by 14


Related Papers